| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,978 | 2,002 | 18.11. | |
| 1,947 | 2,044 | 18.11. |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Minerva Neurosciences, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 06.11. | Minerva Neurosciences, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 06.11. | Minerva Neurosciences GAAP EPS of -$0.19 misses by $0.01 | 2 | Seeking Alpha | ||
| 06.11. | Minerva Neurosciences reports Q3 results, Phase 3 data due 2H 2027 | 1 | Investing.com | ||
| MINERVA NEUROSCIENCES Aktie jetzt für 0€ handeln | |||||
| 06.11. | Minerva Neurosciences, Inc: Minerva Neurosciences Provides Third Quarter 2026 Financial Results and Business Updates | 2 | GlobeNewswire (USA) | ||
| 06.11. | Minerva Neurosciences, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 29.10. | Minerva Neurosciences, Inc: Minerva Neurosciences to Participate in 2026 Jefferies Global Healthcare Conference in London | 329 | GlobeNewswire (Europe) | BURLINGTON, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous... ► Artikel lesen | |
| 28.10. | Minerva Neurosciences, Inc: Minerva Neurosciences to Host In-Person KOL Event to Discuss Roluperidone for Negative Symptoms of Schizophrenia | 476 | GlobeNewswire (Europe) | BURLINGTON, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous... ► Artikel lesen | |
| 28.08. | Minerva Neurosciences, Inc: Minerva Neurosciences to Participate in Two Upcoming Investor Conferences | 887 | GlobeNewswire (Europe) | BURLINGTON, Mass., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous... ► Artikel lesen | |
| 14.08. | Jefferies upgrades Minerva Neurosciences stock rating on regulatory pathway | 5 | Investing.com | ||
| 07.08. | Minerva Neurosciences, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 07.08. | Minerva Neurosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.08. | Minerva Neurosciences, Inc: Minerva Neurosciences Provides Second Quarter 2026 Financial Results and Business Updates | 1.176 | GlobeNewswire (Europe) | Confirmatory Phase 3 trial of roluperidone (MIN-101C19) ongoing with topline efficacy data expected 2H 2027
Scientific Advisory Board of leading experts in psychiatry and neuroscience established... ► Artikel lesen | |
| 04.06. | Minerva Neurosciences, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 01.06. | Minerva Neurosciences, Inc: Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs | 502 | GlobeNewswire (Europe) | Distinguished panel of experts in psychiatry and neuroscience appointed to guide Phase 3 confirmatory trial of roluperidone and broader R&D strategyBURLINGTON, Mass., June 01, 2026 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| 27.05. | Minerva Neurosciences, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 18.05. | Minerva Neurosciences, Inc: Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference | 486 | GlobeNewswire (Europe) | BURLINGTON, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous... ► Artikel lesen | |
| 05.05. | Minerva Neurosciences, Inc: Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates | 1.363 | GlobeNewswire (Europe) | Confirmatory Phase 3 trial of roluperidone for negative symptoms of schizophrenia initiated and first patient screened
Previous open label trial data presented at SIRS 2026 showed no safety or drug-drug... ► Artikel lesen | |
| 02.04. | Minerva Neurosciences, Inc: Minerva Announces Leadership Transition | 693 | GlobeNewswire (Europe) | Jim O'Connor joins as Chief Business Officer and General CounselBURLINGTON, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company... ► Artikel lesen | |
| 31.03. | Minerva Neurosciences, Inc: Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia | 685 | GlobeNewswire (Europe) | Roluperidone has been de-risked by consistent positive results in two prior pivotal trials and remains the only late-stage drug candidate for this high-need population
Efficacy topline data expected... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 76,60 | -0,07 % | BioNTech-Aktie: Totes Kapital? | Die Aktie von BioNTech bleibt trotz des rückläufigen Impfstoffgeschäfts ein spannender Titel am Aktienmarkt. Anleger richten ihren Blick zunehmend auf die milliardenschwere Forschungspipeline im Bereich... ► Artikel lesen | |
| EVOTEC | 2,728 | -0,80 % | Evotec-Aktie: Gewinn- und Umsatzrekord? | Die Aktie des Hamburger Wirkstoffforschers Evotec bleibt ein spannender, aber risikoreicher Titel am deutschen Aktienmarkt. Nach schwierigen Monaten sorgen erste operative Fortschritte, neue Partnerschaften... ► Artikel lesen | |
| MEDIGENE | 0,003 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 30.06.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 30.06.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 30.06.2026ISIN NameBE0003593044 COFINIMMOCA8765111064 TASEKO... ► Artikel lesen | |
| QIAGEN | 45,200 | 0,00 % | QIAGEN N.V.: QIAGEN Shareholders Overwhelmingly Approve Jonathan M. Pratt as Managing Director | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that shareholders overwhelmingly approved the appointment of Jonathan M. Pratt as a Managing Director and member of the QIAGEN... ► Artikel lesen | |
| MODERNA | 179,14 | -0,08 % | Ihre wichtigsten Termine: Heute im Blickpunkt: Moderna, DocMorris, Applied Materials, Siemens und Cisco | © Foto: Bodo Schackow/dpaGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag Enthaltene Werte: DE0008404005... ► Artikel lesen | |
| AMGEN | 405,10 | +0,19 % | Argus raises Amgen stock price target on pipeline strength | ||
| VALNEVA | 2,411 | -1,23 % | Valneva-Aktie über der 50-Tage-Linie: Positive Shigella-Daten treiben an | ||
| EPIGENOMICS | 0,870 | 0,00 % | PTA-PVR: Epigenomics AG: Veröffentlichung nach § 40 Abs. 1 WpHG | DJ PTA-PVR: Epigenomics AG: Veröffentlichung nach § 40 Abs. 1 WpHG
Veröffentlichung gem. -- 40 Abs. 1 WpHG
Epigenomics AG: Veröffentlichung nach -- 40 Abs. 1 WpHG
Heidelberg (pta000/26.10.2026/15:00... ► Artikel lesen | |
| NOVAVAX | 7,180 | -0,97 % | Novavax: Warum der Zahlen-Erfolg nicht alle überzeugt | ||
| BIOGEN | 227,05 | -0,85 % | Biogen Reports Two-Year Data Showing Continued Benefit Of Dianersen In Early Alzheimer's Disease | WESTON (dpa-AFX) - Biogen (BIIB) presented new Phase 2 data showing that diranersen, an investigational therapy targeting the tau protein, continued to slow disease progression in people with... ► Artikel lesen | |
| BIOFRONTERA | 2,820 | -3,09 % | Biofrontera AG: Liquidität unter Druck - was jetzt zählt | ||
| HEIDELBERG PHARMA | 2,010 | -1,47 % | Formycon, Heidelberg Pharma und Medios: Drei Biotech-Nebenwerte, drei völlig unterschiedliche Signale - Formycon hat die Analysten auf seiner Seite | ||
| ILLUMINA | 191,14 | -0,07 % | Illumina Stock Outlook: Is Wall Street Bullish or Bearish? | ||
| CRISPR THERAPEUTICS | 36,890 | +0,71 % | 99 Millionen Dollar mit neuer Gentherapie: Vertex und CRISPR Therapeutics legen zu - Mesoblast wächst um 44 Prozent | ||
| NANOREPRO | 1,395 | -0,71 % | NanoRepro nach starkem H1-Bericht: Diese Marke entscheidet jetzt |